PODD (Insulet) Additional Paid-In Capital : $1,261 Mil(As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is Insulet Additional Paid-In Capital?

Insulet's quarterly additional paid-in capital increased from Sep. 2024 ($1,159 Mil) to Dec. 2024 ($1,184 Mil) and increased from Dec. 2024 ($1,184 Mil) to Mar. 2025 ($1,261 Mil).

Insulet's annual additional paid-in capital increased from Dec. 2022 ($1,041 Mil) to Dec. 2023 ($1,103 Mil) and increased from Dec. 2023 ($1,103 Mil) to Dec. 2024 ($1,184 Mil).

Insulet Additional Paid-In Capital Historical Data

The historical data trend for Insulet's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Additional Paid-In Capital Chart

Insulet Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

1,264.30

1,207.90

1,040.60

1,102.60

1,184.40

Insulet Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															1,117.60	1,140.60	1,158.60	1,184.40	1,260.90

Insulet Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Insulet Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Insulet's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Insulet Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

GOV:Germany GOV:Germany

Address

100 Nagog Park, Acton, MA, USA, 01720

Website

https://www.insulet.com

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

Executives

Frederick Wayne A.i.	director	500 W MAIN ST., LOUISVILLE KY 40202
Eric Benjamin	officer: SVP, R&D, New Prod Dev. & Comm	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DR, SUITE 200, BILLERICA MA 01821
Lauren Budden	officer: VP, CAO and Controller	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Luciana Borio	director	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Jessica Hopfield	director	C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Mark N Field	officer: SVP & Chief Technology Officer	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Prem Singh	officer: SVP, Global Operations	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Shacey Petrovic	officer: CCO	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
James Hollingshead	director	C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan	officer: EVP, CFO	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea	officer: SVP, Chief HR Officer	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue	director	22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin	officer: SVP, Reg, Quality & Compliance	C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Charles Alpuche	officer: SVP, Global Manufacturing	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821